Cases
Rockwell Medical, Inc. (NASDAQ: RMTI)
Securities Class Action
Overview
Overview
- Date:
- 6/26/2019
- Company Name:
- Rockwell Medical, Inc.
- Stock Symbol:
- RMTI
- Class Period:
- FROM 11/8/2017 TO 6/26/2018
- Status:
- Closed/Complete
NEW YORK, June 26, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against Rockwell Medical, Inc. (NASDAQ: RMTI) on behalf of Rockwell stockholders. Our investigation concerns whether Rockwell has violated the federal securities laws and/or engaged in other unlawful business practices.
On July 27, 2018, a complaint was filed alleging that between November 8, 2017 and June 26, 2018, defendants made false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that the Centers for Medicare and Medicaid Services would not pursue Rockwell’s proposal for separate reimbursement for Triferic; (2) the estimated reserves in Rockwell’s Form 10-Q for the quarter ended March 31, 2018 were misstated; (3) there was a material weakness in Rockwell’s internal control over financial reporting; (4) consequently, Rockwell’s internal control over financial reporting was ineffective during the Class Period; (5) Robert L. Chioini, former Chief Executive Officer of Rockwell, withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of Rockwell’s Board; and (6) as a result, defendants’ statements about Rockwell’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
If you purchased or otherwise acquired Rockwell shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On July 27, 2018, a complaint was filed alleging that between November 8, 2017 and June 26, 2018, defendants made false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that the Centers for Medicare and Medicaid Services would not pursue Rockwell’s proposal for separate reimbursement for Triferic; (2) the estimated reserves in Rockwell’s Form 10-Q for the quarter ended March 31, 2018 were misstated; (3) there was a material weakness in Rockwell’s internal control over financial reporting; (4) consequently, Rockwell’s internal control over financial reporting was ineffective during the Class Period; (5) Robert L. Chioini, former Chief Executive Officer of Rockwell, withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of Rockwell’s Board; and (6) as a result, defendants’ statements about Rockwell’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
If you purchased or otherwise acquired Rockwell shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.